Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PLX PHARMA INC.

(PLXP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

PLx Pharma : Addresses 'Confusion' Over US Preventive Services Task Force Recommendations on Aspirin Therapy; Shares Down

10/14/2021 | 02:39pm EST


ę MT Newswires 2021
All news about PLX PHARMA INC.
11/22PLx Pharma Inc. to Present at Piper Sandler 33rd Annual Healthcare Conference 2021
AQ
11/12PLx Pharma Inc. Reports Third Quarter 2021 Results and Provides Business Update - Form ..
PU
11/12PLX PHARMA INC. : Results of Operations and Financial Condition, Change in Directors or Pr..
AQ
11/12PLX PHARMA INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
11/12PLx Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Se..
CI
11/12Earnings Flash (PLXP) PLX PHARMA Posts Q3 Revenue $6.6M, vs. Street Est of $4.1M
MT
11/12Earnings Flash (PLXP) PLX PHARMA Posts Q3 Loss $-0.37
MT
11/12PLx Pharma Inc. Reports Third Quarter 2021 Results and Provides Business Update
AQ
11/04PLx Pharma Inc. Announces New Scientific Data Available Evaluating the Pharmacologic Pr..
GL
11/04PLx Pharma Inc. Announces New Scientific Data Available Evaluating the Pharmacologic Pr..
CI
More news
Analyst Recommendations on PLX PHARMA INC.
More recommendations
Financials (USD)
Sales 2021 8,65 M - -
Net income 2021 -71,9 M - -
Net Debt 2021 - - -
P/E ratio 2021 -2,88x
Yield 2021 -
Capitalization 240 M 240 M -
Capi. / Sales 2021 27,7x
Capi. / Sales 2022 6,93x
Nbr of Employees 10
Free-Float 90,1%
Chart PLX PHARMA INC.
Duration : Period :
PLx Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PLX PHARMA INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 8,70 $
Average target price 24,00 $
Spread / Average Target 176%
EPS Revisions
Managers and Directors
Natasha Giordano President, Chief Executive Officer & Director
Rita M. O'Connor CFO, Head-Manufacturing & Supply Chain
Michael J. Valentino Executive Chairman
Gary S. Balkema Independent Director
Kirk K. Calhoun Independent Director
Sector and Competitors
1st jan.Capi. (M$)
PLX PHARMA INC.59.06%240
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010
ELI LILLY AND COMPANY47.55%222 641